- Home
- PSNYW vs ALEC Comparison
PSNYW vs ALEC Comparison
Compare PSNYW & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNYW | ALEC |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Sweden | United States |
| Employees | 1686 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.9M | 245.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PSNYW | ALEC |
|---|---|---|
| Price | $3.27 | $2.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 4.7K | ★ 618.7K |
| Earning Date | 03-06-2025 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,034,261,000.00 | $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | $79.49 | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.14 | $1.09 |
| 52 Week High | $7.50 | $3.40 |
Technical Indicators
Market Signals| Indicator | PSNYW | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 42.61 |
| Support Level | $2.88 | $1.93 |
| Resistance Level | $3.51 | $2.64 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 40.58 | 29.17 |
Price Performance
Historical ComparisonAbout PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.